Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Investigational drug notice
Retatrutide has not been approved by the FDA. It is in phase 3 clinical trials and is not legally available outside those trials. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. The information on this page is educational and references published clinical trial data. Anyone considering changes to their current weight-management regimen should consult their prescribing clinician.
Key Takeaways
- Mounjaro is the brand name for tirzepatide in type 2 diabetes; Zepbound is the same molecule branded for obesity. Both are made by Eli Lilly
- Retatrutide is also from Eli Lilly and adds glucagon receptor agonism to tirzepatide's dual GLP-1/GIP mechanism
- Cross-trial: retatrutide phase 2 (24.2% at 12 mg over 48 weeks) versus SURMOUNT-1 tirzepatide (22.5% at 15 mg over 72 weeks). The gap is modest
- Switching is not currently possible because retatrutide is not approved. Earliest realistic timeline is 2027-2028
- For patients responding well on tirzepatide, there is no clinical reason to plan a switch in advance. For patients who plateau, the conversation is different but the option is still future tense
Direct answer
You cannot switch from tirzepatide to retatrutide today. Retatrutide is investigational, not FDA-approved, and not legally available outside clinical trials. Even when it does approve (projected 2027 or later), the case for switching is patient-specific. Cross-trial data shows retatrutide phase 2 produced slightly more weight loss than SURMOUNT-1 tirzepatide, but the trials are not directly comparable and the gap is small. Patients responding well on tirzepatide rarely benefit from switching to a similar drug class; patients who plateau may eventually have new options.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The two drugs in plain language
- Cross-trial efficacy comparison
- Mechanism: what the third receptor adds
- Why "switching" is the wrong question right now
- The plateau scenario: when switching makes sense
- What a future transition might look like
- Side effect profile compared
- Cardiovascular and metabolic outcome data
- Decision framework: stay, optimize, or wait
- The contrary view: tirzepatide is probably enough for most people
- FAQ
- Sources
The two drugs in plain language
Tirzepatide (Mounjaro, Zepbound) is a once-weekly injectable that activates two gut hormone receptors: GLP-1 and GIP. It received FDA approval for type 2 diabetes in May 2022 (as Mounjaro) and for chronic weight management in November 2023 (as Zepbound).
Retatrutide is also a once-weekly injectable from Eli Lilly. It activates three receptors: GLP-1, GIP, and glucagon. The phase 2 trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity and tested doses from 1 mg to 12 mg over 48 weeks. Phase 3 trials (the TRIUMPH program) are running through 2026-2027.
Both drugs come from the same manufacturer. Lilly is positioning retatrutide as a next-generation option targeting patients who need more weight loss than tirzepatide alone can achieve, or who have specific metabolic profiles where the added glucagon agonism may help.
Cross-trial efficacy comparison
| Tirzepatide (SURMOUNT-1) | Retatrutide (phase 2) | |
|---|---|---|
| Citation | Jastreboff et al., NEJM 2022 | Jastreboff et al., NEJM 2023 |
| Phase | Phase 3 pivotal | Phase 2 |
| Sample size | 2,539 | 338 |
| Duration | 72 weeks | 48 weeks |
| Mean baseline BMI | 38.0 | 37.3 |
| Top dose | 15 mg weekly | 12 mg weekly |
| Mean weight loss at top dose | 22.5% | 24.2% |
| Mean weight loss at 48 weeks (matched timepoint) | ~19% (estimated from published curve) | 24.2% |
| Placebo arm | 2.4% | 2.1% |
| FDA status | Approved (Mounjaro 2022, Zepbound 2023) | Not approved |
At 72 weeks the SURMOUNT-1 tirzepatide curve had largely plateaued. At 48 weeks the retatrutide phase 2 curve had not. Projecting retatrutide to 72 weeks would likely add a few percentage points to the mean. The cross-trial gap at endpoint is small enough that head-to-head data could erase it, but the directional signal favors retatrutide.
Mechanism: what the third receptor adds
Tirzepatide hits GLP-1 and GIP. The GLP-1 component drives most of the appetite reduction and glycemic effect. The GIP component appears to amplify satiety signaling and improve glucose handling in ways that account for a meaningful share of tirzepatide's advantage over single GLP-1 agonists like semaglutide.
Retatrutide adds glucagon receptor agonism. Glucagon is famous for raising blood sugar, which sounds backwards in a diabetes or obesity drug. The trick is that glucagon also increases resting energy expenditure, promotes hepatic fatty acid oxidation, and has direct effects on adipose tissue. In a triple agonist, the glucose-lowering effects of GLP-1 and GIP balance the glucose-raising effect of glucagon, and the net result preserves glycemic benefit while capturing the metabolic-rate increase.
The clinical signal of the glucagon mechanism: retatrutide patients in phase 2 had reductions in liver fat that appeared larger than what tirzepatide produces, and the dose-response for weight loss was steeper at low doses than tirzepatide's. Both observations are consistent with the glucagon hypothesis.
Why "switching" is the wrong question right now
Patients who are on Mounjaro or Zepbound today and asking about retatrutide are usually doing one of three things: hedging against future treatment options, planning for a hypothetical plateau, or expressing dissatisfaction with their current results.
The honest response to each:
For patients hedging: there is nothing to do. Retatrutide is not available. Plan for tirzepatide-based treatment for the next 18-30 months minimum. Revisit the question when phase 3 data publishes and approval timelines firm up.
For patients planning around a future plateau: most patients on tirzepatide do not hit a hard plateau. They reach a maintenance weight that is meaningfully lower than baseline and stay there with continued treatment. The plateau scenario is real but not universal. Pre-planning a switch for a problem that may not arise is rarely useful.
For patients dissatisfied with current results: that is a current-treatment optimization question, not a future-drug question. Check the dose. Check adherence. Check whether the patient has actually been on a stable maintenance dose for long enough to evaluate response (16-24 weeks at maintenance is the usual minimum). Most "tirzepatide is not working" cases are actually titration, behavioral, or expectation issues, not drug failures.
The plateau scenario: when switching makes sense
Some patients do plateau on tirzepatide before reaching their clinical or personal weight-loss goal. The pattern usually looks like:
- Steady weight loss over the first 6-12 months
- Plateau at a maintenance weight that is 15-22% below baseline
- No further loss despite continued treatment at maximum tolerated dose
- Continued metabolic and quality-of-life benefit, even without further weight loss
In that pattern, the question of whether retatrutide would push past the plateau is genuine. The phase 2 dose-response data suggests retatrutide might produce another 3-7 percentage points of weight loss in this population, particularly through the metabolic-rate increase that single and dual agonists do not access. The data is too thin to be confident.
For the plateau scenario, the realistic 2026 options are: maintain current tirzepatide dose and accept the maintenance weight, optimize behavioral and nutritional support, consider adjunctive medications (phentermine for short-term, naltrexone-bupropion for some patients), or evaluate for metabolic and bariatric surgery if BMI and comorbidities meet criteria. Retatrutide is not yet on this list.
What a future transition might look like
If retatrutide approves in 2027 with a label similar to current obesity medications, the likely transition protocol from tirzepatide would resemble standard within-class switches. The general principles for incretin medication transitions:
- Stop the current medication at the end of a dose interval (one week after last injection)
- Start the new medication at the lowest titration dose, not the equivalent dose
- Titrate up over the standard schedule of the new drug
- Expect a transient gap in coverage during the dose ramp
The actual approved retatrutide label will specify titration. Individual transition decisions should wait for that data and be made with the prescribing clinician. Do not design your own transition off-label.
Side effect profile compared
| Adverse event | Tirzepatide SURMOUNT-1 (15 mg) | Retatrutide phase 2 (12 mg) |
|---|---|---|
| Nausea | ~33% | ~36% |
| Diarrhea | ~21% | ~27% |
| Vomiting | ~15% | ~16% |
| Constipation | ~17% | ~14% |
| Discontinuation for AE | ~7% | ~6-12% (varied by dose) |
| Heart rate increase | ~3 bpm | ~3-4 bpm |
| Hypoglycemia (non-diabetic) | Rare | Rare |
The profiles are similar in shape. Retatrutide had marginally higher diarrhea rates and slightly faster heart rate response, which fits with the added glucagon receptor activity. None of the cross-trial differences are large enough to be confident in a head-to-head setting.
Cardiovascular and metabolic outcome data
Tirzepatide has the SURPASS-CVOT trial running (cardiovascular outcomes in type 2 diabetes) with anticipated readout in 2025-2026. SURMOUNT-MMO (morbidity and mortality outcomes in obesity) reads out later. There is no published cardiovascular outcome data for retatrutide yet.
For patients with established cardiovascular disease and obesity, the SELECT trial of semaglutide (Lincoff et al., NEJM 2023) showed a 20% reduction in major adverse cardiovascular events versus placebo. Whether tirzepatide and retatrutide produce similar effects is unproven but expected based on shared mechanism class.
A patient currently on tirzepatide because of CV-prevention reasoning should stay on tirzepatide until outcome data exists for any alternative. Switching from a drug with anticipated CV benefit to an unstudied drug for marginal extra weight loss is a bad trade.
Decision framework: stay, optimize, or wait
Stay if: tirzepatide is working, you tolerate it, you have reached or are approaching your weight-management goal, you have cardiovascular or metabolic risk factors where established benefit matters.
Optimize if: you are not yet at maintenance dose, your adherence has gaps, your diet or sleep pattern is not aligned with the medication's mechanism, your dose titration was rushed and side effects pushed you below an effective maintenance dose.
Wait if: you have plateaued despite optimization, you have specific reasons (liver fat, metabolic features) where retatrutide's mechanism may help, you have time to delay further weight-loss progression by 1-2 years without significant clinical cost.
Do not switch outside approved channels. The supply that exists outside clinical trials cannot be verified for purity, identity, or dose. Adverse events on unverified retatrutide are not covered by typical informed consent or post-event support structures.
The contrary view: tirzepatide is probably enough for most people
The "wait for retatrutide" framing assumes that more weight loss is always better. For some patients, that's true. For many, it is not.
Twenty percent weight loss over 18 months on tirzepatide already produces most of the cardiovascular, metabolic, and quality-of-life benefit available from pharmacotherapy. Pushing from 20% to 25% weight loss adds marginal benefit, while every increment of additional weight loss carries proportionally more risk: muscle mass preservation becomes harder, micronutrient gaps appear, gallstone risk rises, energy availability for activity may drop.
The triple agonist class may end up being most useful in two specific populations: patients with severe obesity (BMI 40+) where larger absolute weight loss is needed to address comorbidities, and patients with metabolic dysfunction-associated liver disease where the glucagon component may provide hepatic-specific benefit. For the middle of the bell curve, the existing dual-agonist class is probably already enough.
Reframing the question: "Should I switch to retatrutide?" can become "Is the weight loss I am getting on tirzepatide producing the health outcomes I need?" If yes, the answer is to stay. If no, the next step is usually a clinical reassessment, not a hypothetical drug change.
FAQ
Is Mounjaro the same as tirzepatide? Yes. Mounjaro is the brand name. Tirzepatide is the generic. Zepbound is the same molecule under a different brand for the obesity indication.
Is retatrutide stronger than Mounjaro? Cross-trial, retatrutide phase 2 produced slightly more weight loss than SURMOUNT-1 tirzepatide. The difference is modest and the trials are not directly comparable.
Can my doctor prescribe retatrutide? Not legally. The drug is not FDA-approved. The only legitimate way to receive retatrutide today is through enrollment in an active clinical trial.
Will retatrutide replace tirzepatide? Unlikely to fully replace. More likely to position as a next-tier option for patients who need more weight loss or have specific metabolic features.
What if I want to switch as soon as it's approved? Have that conversation with your prescriber after approval and after the FDA label is published. The transition specifics will depend on what the approved dosing and titration look like.
Are the long-term effects of retatrutide known? No. Phase 2 data covers 48 weeks. Phase 3 trials are running 72 weeks or longer. Post-marketing surveillance after eventual approval will produce the longer-term picture over years.
Does FormBlends provide retatrutide? No. FormBlends connects patients with licensed providers for FDA-approved and compounded semaglutide and tirzepatide where clinically appropriate. We do not provide retatrutide.
If retatrutide has glucagon activity, will it raise my blood sugar? Phase 2 results showed no clinically meaningful increase in fasting glucose or HbA1c in non-diabetic patients. In type 2 diabetic patients (phase 2 diabetes trial, Rosenstock et al., Lancet 2023), retatrutide actually lowered HbA1c. The net glucagon effect appears to be outweighed by GLP-1 and GIP at therapeutic doses.
Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023;402:529-540.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
- FDA. Mounjaro (tirzepatide) Prescribing Information. Approved May 2022.
- FDA. Zepbound (tirzepatide) Prescribing Information. Approved November 2023.
- ClinicalTrials.gov. TRIUMPH-1 through TRIUMPH-5 phase 3 retatrutide program.
- Eli Lilly investor relations materials, 2024-2026.
- American Diabetes Association. Standards of Medical Care in Diabetes, 2026.
- Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity, 2024 Update.
- Garvey WT et al. Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocrine Practice. 2022.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital telehealth platform that matches patients with independent licensed clinicians and U.S.-based pharmacies. Treatment decisions are made by the patient and the prescribing provider. FormBlends does not itself prescribe or dispense.
Compounded Medication Notice. Compounded tirzepatide is prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. Compounded medications are not FDA-approved. They are not interchangeable with Mounjaro or Zepbound.
Investigational Drug Notice. Retatrutide is investigational and under FDA review through the phase 3 TRIUMPH trial program. It is not approved for any indication. FormBlends does not sell, supply, or facilitate access to retatrutide. Discussion on this page references published peer-reviewed trial data.
Results Disclaimer. Clinical trial means describe average outcomes in study populations. Individual response varies based on adherence, baseline metabolic profile, lifestyle, and biological variation. Trial percentages should not be interpreted as guaranteed personal outcomes.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is a development-stage compound from Eli Lilly. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly or Novo Nordisk.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →